Company registration number SC758899 (Scotland)
SL PATHOLOGY LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025
PAGES FOR FILING WITH REGISTRAR
SL PATHOLOGY LTD
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 4
SL PATHOLOGY LTD
BALANCE SHEET
AS AT
28 FEBRUARY 2025
28 February 2025
- 1 -
28 February 2025
29 February 2024
Notes
£
£
£
£
Fixed assets
Tangible assets
4
1,159
-
0
Current assets
Debtors
5
3,164
2,883
Cash at bank and in hand
24,186
10,525
27,350
13,408
Creditors: amounts falling due within one year
6
(4,746)
(3,550)
Net current assets
22,604
9,858
Total assets less current liabilities
23,763
9,858
Provisions for liabilities
(220)
-
0
Net assets
23,543
9,858
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
23,443
9,758
Total equity
23,543
9,858

For the financial year ended 28 February 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 13 November 2025
Dr S Liptrot
Director
Company registration number SC758899 (Scotland)
SL PATHOLOGY LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 28 FEBRUARY 2025
- 2 -
1
Accounting policies
Company information

SL Pathology Ltd is a private company limited by shares incorporated in Scotland. The registered office is 6th Floor, Gordon Chambers, 90 Mitchell Street, Glasgow, Scotland, G1 3NQ.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Turnover

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Computers
33% on a straight line basis

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

SL PATHOLOGY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2025
1
Accounting policies
(Continued)
- 3 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
1
1
SL PATHOLOGY LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 28 FEBRUARY 2025
- 4 -
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 March 2024
-
0
Additions
1,730
At 28 February 2025
1,730
Depreciation and impairment
At 1 March 2024
-
0
Depreciation charged in the year
571
At 28 February 2025
571
Carrying amount
At 28 February 2025
1,159
At 29 February 2024
-
0
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Other debtors
3,164
2,883
6
Creditors: amounts falling due within one year
2025
2024
£
£
Corporation tax
3,005
2,354
Other creditors
1,741
1,196
4,746
3,550
2025-02-28 2024-03-01 false false false CCH Software CCH Accounts Production 2025.200 No description of principal activity Dr S Liptrot SC758899 2024-03-01 2025-02-28 SC758899 2025-02-28 SC758899 2024-02-29 SC758899 core:OtherPropertyPlantEquipment 2025-02-28 SC758899 core:OtherPropertyPlantEquipment 2024-02-29 SC758899 core:ShareCapital 2025-02-28 SC758899 core:ShareCapital 2024-02-29 SC758899 core:RetainedEarningsAccumulatedLosses 2025-02-28 SC758899 core:RetainedEarningsAccumulatedLosses 2024-02-29 SC758899 bus:Director1 2024-03-01 2025-02-28 SC758899 core:ComputerEquipment 2024-03-01 2025-02-28 SC758899 2023-02-15 2024-02-29 SC758899 core:OtherPropertyPlantEquipment 2024-02-29 SC758899 core:OtherPropertyPlantEquipment 2024-03-01 2025-02-28 SC758899 core:WithinOneYear 2025-02-28 SC758899 core:WithinOneYear 2024-02-29 SC758899 core:CurrentFinancialInstruments 2025-02-28 SC758899 core:CurrentFinancialInstruments 2024-02-29 SC758899 bus:PrivateLimitedCompanyLtd 2024-03-01 2025-02-28 SC758899 bus:SmallCompaniesRegimeForAccounts 2024-03-01 2025-02-28 SC758899 bus:FRS102 2024-03-01 2025-02-28 SC758899 bus:AuditExempt-NoAccountantsReport 2024-03-01 2025-02-28 SC758899 bus:FullAccounts 2024-03-01 2025-02-28 xbrli:pure xbrli:shares iso4217:GBP